（文章来源：证券日报） 证券日报网讯 11月3日晚间，海思科发布公告称，公司于近日收到国家药品监督管理局审评中心下发的 《药物临床试验批准通知书》，药品名称：HSK39297片。 ...

格隆汇11月3日丨海思科(002653.SZ)公布，近日收到国家药品监督管理局审评中心下发的《药物临床试 验批准通知书》，根据《中华人民共和国药品管理法》及有关规定，经审查，2025年8月受理的 HSK39297片临床试验申请符合药品注册的有关要求，同意本品开展临床试验。HSK39297片是公司自主 研发的全新的具有独立知识产权的治疗全身型重症肌无力的药物。 ...

海思科11月3日公告，公司收到国家药品监督管理局审评中心下发的《药物临床试验批准通知书》，同 意HSK39297片开展临床试验。该药物为公司自主研发的治疗全身型重症肌无力的小分子药物，具有明 确的靶点、确切的疗效和良好的安全性。 ...

海思科（002653）(002653.SZ)公告，公司近日收到国家药品监督管理局审评中心下发的《药物临床试 验批准通知书》，药品名称为HSK39297片，其适应症为全身型重症肌无力。 ...

海思科公告，近日收到国家药品监督管理局审评中心下发的《药物临床试验批准通知书》，同意公司创 新药HSK39297片开展全身型重症肌无力的临床试验。HSK39297片是公司自主研发的全新小分子药物， 临床前研究显示其靶点明确、疗效确切、安全性好，有望成为全身型重症肌无力的有效治疗药物。 ...

重症肌无力（MG）是一种神经-肌肉接头（neuromuscular junction，NMJ）传递障碍的自身免疫性疾病。流行病学显示，MG 全 球患病率为（150-250）/百万，预估年发病率为（4-10）/百万。MG 可导致全身骨骼肌受累，随着病情进展可发展为全身型重症肌无力 海思科医药集团股份有限公司 关于获得创新药 HSK39297 片新适应症 《药物临床试验批准通知书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"） 于近日收 到国家药品监督管理局审评中心下发的《药物临床试验批准通知书》， 现将相关情况公告如下： | 药品名称 | | 剂型 | 适应症 | 申请事项 | 受理号 | | --- | --- | --- | --- | --- | --- | | HSK39297 | 片 | 片剂 | 全身型重症 | 境内生产药品 | CXHL2500854 | | | | | 肌无力 | 注册临床试验 | CXHL2500855 | 根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 ...

Core Insights - The company, Haikang, was established on August 26, 2005, and went public on January 17, 2012, on the Shenzhen Stock Exchange, focusing on the research, production, and sales of chemical pharmaceuticals, with notable performance in innovative drug development [1] Financial Performance - For Q3 2025, Haikang reported revenue of 3.3 billion yuan, ranking 21st among 110 companies in the industry, while the net profit was 295 million yuan, ranking 29th [2] - The company's revenue growth year-over-year was 19.95%, while the net profit decreased by 22.66% [6] Profitability and Debt - As of Q3 2025, Haikang's debt-to-asset ratio was 41.43%, higher than the industry average of 35.26%, indicating a need to monitor debt risks [3] - The gross profit margin was 73.90%, above the industry average of 57.17%, suggesting strong profitability potential for the company's products [3] Leadership Compensation - The chairman, Wang Junmin, received a salary of 1.7525 million yuan in 2024, a decrease of 12,900 yuan from the previous year [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 12.87% to 12,900, while the average number of shares held per shareholder decreased by 11.40% [5] Innovation and Future Prospects - The company has launched four innovative drugs that are rapidly gaining market share, with expectations for significant growth in sales [6] - Several early-stage products are progressing in clinical trials, with potential for international market entry [6]

证券之星消息，10月31日，医疗健康R（480016）指数报收于7755.61点，涨1.68%，成交401.03亿元，换 手率1.25%。当日该指数成份股中，上涨的有43家，泽璟制药以16.14%的涨幅领涨，下跌的有6家，凯莱 英以4.33%的跌幅领跌。 | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300760 迈瑞医疗 | | 2.62 亿 | 11.16% | -1.27 Z | -5.42% | -1.34 Z | -5.74% | | 688235 百济神州 | | 2.33 Z | 13.90% | -2.25 Z | -13.41% | -810.20万 | -0.48% | | 002653 | 海思科 | 9277.82万 | 16.28% | 313.75万 | - 0.55% | -9591.57万 | -16.83% | | 002001 | 新和成 | 9037.75万 | 12.87% | ...

Core Insights - The innovative drug sector has seen a rise of 3.35%, ranking fifth among various concept sectors, with 248 stocks increasing in value, including notable gainers like Shuyou Pharmaceutical and Sanofi, which hit the 20% limit up [1][2] - Major inflows of capital into the innovative drug sector amounted to 3.783 billion yuan, with 138 stocks receiving net inflows, and 13 stocks exceeding 100 million yuan in net inflows, led by Shuyou Pharmaceutical with 464 million yuan [2][3] Sector Performance - The innovative drug sector's performance was highlighted by significant stock price increases, with Shuyou Pharmaceutical rising by 19.99%, Lianhuan Pharmaceutical by 10.01%, and Zhongsheng Pharmaceutical by 10.02% [3][4] - The sector's top gainers included Kangzhi Pharmaceutical, Zaiqiang Pharmaceutical, and Yifang Biotechnology, which saw increases of 17.47%, 16.14%, and 15.30% respectively [1][2] Capital Inflow Analysis - Lianhuan Pharmaceutical, Anglikang, and Yatai Pharmaceutical led in capital inflow ratios, with net inflow rates of 41.17%, 33.00%, and 21.24% respectively [3] - The top stocks by net capital inflow included Shuyou Pharmaceutical, Lianhuan Pharmaceutical, and Zhongsheng Pharmaceutical, with net inflows of 464 million yuan, 349 million yuan, and 305 million yuan respectively [2][3] Market Trends - The overall market for innovative drugs is experiencing positive momentum, with a significant number of stocks showing strong performance and attracting substantial capital investment [1][2] - The sector's resilience is evident as it continues to attract investor interest despite fluctuations in other sectors, indicating a robust outlook for innovative pharmaceuticals [2][3]

Core Viewpoint - The concept of generic drug consistency evaluation has seen a significant increase, with a rise of 3.31% as of the market close on October 31, ranking it seventh among concept sectors [1]. Group 1: Market Performance - Within the generic drug consistency evaluation sector, 135 stocks experienced gains, with notable performers including Zhongsheng Pharmaceutical, Lianhuan Pharmaceutical, and Haishike, all reaching their daily limit up [1]. - The top gainers in this sector were Kangzhi Pharmaceutical, Deyuan Pharmaceutical, and Yuandong Biological, with increases of 17.47%, 13.09%, and 11.45% respectively [1]. - Conversely, Shanghai Pharmaceuticals, *ST Suwu, and Jianfeng Group were among the top decliners, with decreases of 2.07%, 1.98%, and 1.81% respectively [1]. Group 2: Capital Inflow - The generic drug consistency evaluation sector attracted a net inflow of 2.434 billion yuan, with 72 stocks receiving net inflows, and 8 stocks exceeding 100 million yuan in net inflow [2]. - The leading stock in terms of net capital inflow was Yongtai Technology, which saw a net inflow of 397 million yuan, followed by Lianhuan Pharmaceutical and Zhongsheng Pharmaceutical with net inflows of 349 million yuan and 305 million yuan respectively [2]. Group 3: Capital Flow Ratios - Lianhuan Pharmaceutical, Anglikang, and Yatai Pharmaceutical had the highest capital inflow ratios, with net inflow rates of 41.17%, 33.00%, and 21.24% respectively [3]. - The top stocks in the generic drug consistency evaluation sector based on capital inflow included Yongtai Technology, Lianhuan Pharmaceutical, and Zhongsheng Pharmaceutical, with respective daily gains of 6.16%, 10.01%, and 10.02% [3].